Click here Program Slides Download (PDF)
Tumor hypoxia is associated with increased tumor cell proliferation and, therefore, reduced disease-free survival in tumor types that are characterized by hypoxia, such as soft tissue sarcoma (STS). Novel agents targeting the hypoxia response in tumors are currently being investigated in STS. Community clinicians must be aware of these advances and the emerging data from ongoing studies of novel therapies in STS, as well as strategies to integrate new therapies into practice.
This CME activity will update all members of the multidisciplinary cancer care team on the mechanisms of action of novel agents targeting tumor hypoxia and the efficacy and safety data for these therapies. The activity will also explore the challenges faced by community clinicians who manage patients with STS, and provide clinicians with the knowledge and skills to overcome those challenges and improve outcomes.
Jonathan C. Trent, MD, PhD
Director, Bone and Soft-tissue Sarcoma Program
Associate Director for Clinical Research
Sylvester Comprehensive Cancer Center
University of Miami Health Systems
Scott H. Okuno, MD
Professor of Oncology
Aleksandar Sekulic, MD, PhD received his medical doctorate from the University of Zagreb School of Medicine in Croatia, then attended Mayo Graduate School, where he completed the PhD in immunology. He further trained at Mayo Graduate School of Medicine where he completed a residency in dermatology.
Dr. Sekulic's clinical practice focuses on cutaneous oncology, including malignant melanoma and other pigmented lesions, epidermal neoplasms, and cutaneous T-cell lymphoma. His research is centered on developing translational approaches for the study of genomics in skin diseases, identifying the genetics and molecular mechanisms of malignant melanoma, discovering the molecular diagnostics of pigmented lesions, and understanding the regulation of epidermal proliferation and differentiation in human skin disease.
Dr. Sekulic is a recipient of the Excellence in Teaching Recognition Award at Mayo Medical School. He also received the 2012 Gerstner Family Foundation Career Development Award in Individualized Medicine. He has given international, national, and regional presentations and has co-authored several articles, book chapters, and abstracts which have been published in numerous peer-reviewed journals. His research has been funded by the National Cancer Institute and other organizations.
This activity is intended for medical oncologists, pediatric oncologists, pathologists, radiologists, surgeons, and other health care professionals involved in the treatment and care of patients with soft tissue sarcoma.
At the conclusion of this activity, participants should be able to demonstrate the ability to:
• Discuss the current treatment paradigm for soft tissue sarcoma
• Evaluate safety/efficacy data of promising novel agents for the treatment of soft tissue sarcoma
• Review the rationale for targeting hypoxia and the mechanisms of action of novel agents targeting hypoxia in soft tissue sarcoma
• Empower patients to become active participants in their treatment decisions and health management
Welcome and Introductions
Tumor Hypoxia as a Biomarker
Clinical Case Discussions
- A patient with metastatic retroperitoneal leiomyosarcoma who has progressed after receiving chemotherapy
- A patient with metastatic synovial sarcoma benefitting from high-dose ifosfamide with therapeutic limitation due to toxicity
Panel Discussion and Q&A Session
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Potomac Center for Medical Education and Rockpointe Oncology. The Potomac Center for Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The Potomac Center for Medical Education designates this live activity for a maximum of 1.50 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
For questions regarding CME credit, the post-test, or evaluation, please email firstname.lastname@example.org
Potomac Center for Medical Education (PCME) adheres to the policies and guidelines, including the Standards for Commercial Support, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.
All persons in a position to control the content of a continuing medical education program provided by PCME are required to disclose any relevant financial relationships with any commercial interest to PCME as well as to learners. All conflicts of interest are identified and resolved by PCME in accordance with the Standards for Commercial Support in advance of delivery of the activity to learners.
The content of this activity was vetted by an external medical reviewer to assure objectivity and that the activity is free of commercial bias.
Method of Participation
To complete the activity and receive credit, the participant must attend the program and complete the evaluation form. A CME-certificate will be emailed to participants upon submission of a completed evaluation form.
There are no fees associated with this program.
Event staff will be glad to assist you with any specials needs (e.g. physical, dietary, etc.).
Please email specialservices@pcme-Rockpointe.com at least 5 days prior to the program.
Jointly PROVIDED By
This program is supported by an educational grant from EMD Serono.
By clicking the Registration Button below you are agreeing that you have read and understood the CME Statements above.
Registration is for planning purposes only. Seating is limited and will be provided on a first-come, first-served basis.